SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

29 Oct 2021 Evaluate
The company witnessed a 6.36% growth in the revenue at Rs. 3226.61 millions for the quarter ended September 2021 as compared to Rs. 3033.73 millions during the year-ago period.Modest increase of 13.48% in the Net Profit was reported from. 1054.92 millions to Rs. 1197.08  millions.Operating Profit saw a handsome growth to 1446.98 millions from 1223.43 millions in the quarter ended September 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 3226.61 3033.73 6.36 6289.57 5648.54 11.35 11088.34 10202.31 8.68
Other Income 76.54 24.10 217.59 141.01 38.20 269.14 99.98 147.28 -32.12
PBIDT 1446.98 1223.43 18.27 2736.89 2237.71 22.31 4273.12 3703.28 15.39
Interest 7.86 1.96 301.02 12.49 4.14 201.69 7.78 18.54 -58.04
PBDT 1439.12 1221.47 17.82 2724.40 2233.57 21.98 4265.34 3684.74 15.76
Depreciation 116.19 92.11 26.14 228.48 182.65 25.09 376.40 448.82 -16.14
PBT 1322.93 1129.36 17.14 2495.92 2050.92 21.70 3888.94 3235.92 20.18
TAX 125.85 74.44 69.06 231.64 124.69 85.77 382.89 323.18 18.48
Deferred Tax -163.79 -123.83 32.27 -266.21 -237.36 12.15 -318.95 -251.74 26.70
PAT 1197.08 1054.92 13.48 2264.28 1926.23 17.55 3506.05 2912.74 20.37
Equity 135.91 135.78 0.10 135.91 135.78 0.10 135.78 135.78 0.00
PBIDTM(%) 44.85 40.33 11.20 43.51 39.62 9.84 38.54 36.30 6.17

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×